Chongqing Peg-Bio Biopharm Co., Ltd.

Quick facts

Phase 3 pipeline

• PJ009 · Oncology
  PJ009 is a monoclonal antibody targeting PD-1.

Phase 1 pipeline

• PD5K3
• PN20
• PN20 treatment

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Chongqing Peg-Bio Biopharm Co., Ltd. portfolio CI brief
• Chongqing Peg-Bio Biopharm Co., Ltd. pipeline updates RSS